IRulya Therapeutics QNCX Insider Ownership

NASDAQ QNCX

$34.45 +2.42 (+7.56%)

At close: Oct 19, 2026 · 4:00 PM EDT

Insider Holdings by Owner

44.32K Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

0.646%

■0% pp QoQ

Shares Held by Insiders

39.59K

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

6.13Mn

6,132,845 shares

Direct Holdings

15.48K

Indirect: 24.11K

Net Shares Traded (QoQ)

no net change in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 5, 2026

Over the past year, QNCX insiders sold $173,500 of stock on the open market and bought none.

The largest open-market sales of QNCX in the past 12 months were by Luca Benatti (Director), totaling $173,500, most recently on December 26, 2025.
Business Quant data puts insider holdings in QNCX at 39.59K shares across insiders' latest Form 4 filings, or 0.65% of the 6.13Mn shares outstanding; that total is unchanged from 39.59K shares at the end of Q2 2026 and up 0.85% from 39.26K shares (split-adjusted) at the end of Q3 2025.
Of the 39.59K shares held by Quince Therapeutics insiders, 15.48K shares (39.10%) are held directly and 24.11K shares (60.90%) indirectly, through trusts, partnerships, family members and other entities.
QNCX's insider total is spread across 6 insiders who have filed a Form 4 in the past two years.
Quince Therapeutics' three largest insider shareholders, based on their latest Form 4 filings, are David Lamond (Director, 31.92K shares), Dirk Thye (CEO and CMO, 4.97K shares) and Brendan Hannah (CBO, COO & CCO, 1.81K shares).
Of the shares held by QNCX insiders, 80.63% belong to David Lamond.
A total of 13 Form 4 filings with transactions in Quince Therapeutics stock were made over the past 12 months, by 9 insiders.
These insider figures for Quince Therapeutics are based on Form 4 filings through June 15, 2026.

Form 4 Holdings

Insiders Holding QNCX

Insiders 13

Shares held 44.32K

Of outstanding 0.723%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	David Lamond	Director	11,511	11,738	23,249	52.5%	14 Dec, 2023
2	Dirk Thye	Ceo And Cmo	5,495	3,699	9,194	20.7%	11 Dec, 2025
3	Brendan Hannah	Cbo, Coo Cco	3,292	0	3,292	7.4%	06 Dec, 2025
4	Philip S Low	Director	2,277	320	2,596	5.9%	23 May, 2022
5	Christopher P. Lowe	Interim Ceo, Coo Cfo	1,325	0	1,325	3.0%	04 Mar, 2022
6	Charles S. Ryan	President	1,262	0	1,262	2.8%	20 Jun, 2025
7	Karen L. Smith	Chief Medical Officer	973	0	973	2.2%	27 May, 2022
8	Leslie Holsinger	Evp, Preclinical Development	740	0	740	1.7%	08 Jun, 2022
9	Michael J. Detke	Chief Medical Officer	700	0	700	1.6%	04 Mar, 2022
10	Caryn Gordon Mcdowell	Chief Legal Adm. Officer	613	0	613	1.4%	08 Jun, 2022
11	Luca Benatti	Director	196	0	196	0.4%	29 Dec, 2025
12	Ted Monohon	Chief Accounting Officer Vp	137	0	137	0.3%	06 Mar, 2023
13	Margaret Mcloughlin	Director	40	0	40	0.1%	09 Aug, 2023

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

321 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
11 Jun, 2026	David Lamond	Director	Acquired A	2,700	$0.00	$0	135	Direct
11 Jun, 2026	Christopher J. Senner	Director	Acquired A	2,700	$0.00	$0	135	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	34,675	—	—	1,734	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	228,855	—	—	11,443	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	124,830	—	—	6,242	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	69,350	—	—	3,468	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	362,092	—	—	18,105	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	133,615	—	—	6,681	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	2,070,107	—	—	103,505	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	6,837,319	—	—	341,866	Direct
18 May, 2026	Brigette Roberts	Chief Corp. Affairs Officer	Acquired A	6,837,319	—	—	341,866	Direct
23 Jan, 2026	Charles S. Ryan	President	Acquired A	200,000	$0.00	$0	1,000	Direct
23 Jan, 2026	Dirk Thye	Ceo And Cmo	Acquired A	1,000,000	$0.00	$0	5,000	Direct
23 Jan, 2026	Brendan Hannah	Cbo, Coo Cco	Disposed A	365,000	$0.00	$0	1,825	Direct
02 Jan, 2026	Christopher J. Senner	Director	Acquired A	21,810	$0.00	$0	109	Direct
02 Jan, 2026	June Bray	Director	Acquired A	18,724	$0.00	$0	94	Direct
02 Jan, 2026	Margaret Mcloughlin	Director	Acquired A	19,547	$0.00	$0	98	Direct
02 Jan, 2026	David Lamond	Director	Acquired A	29,423	$0.00	$0	147	Direct
26 Dec, 2025	Luca Benatti	Director	Disposed S	50,000	$694.00	$34.70Mn	196	Direct
10 Dec, 2025	Dirk Thye	Ceo And Cmo	Disposed G	739,885	$0.00	$0	1,275	Direct

Showing 1 to 20 of 321 transactions